Primary lymphoma of the ocular adnexa (orbital lymphoma) and primary intraocular lymphoma.

Abstract

Lymphomas of the orbit and eye are rare conditions that should be treated as separate entities due to the differences in presumed aetiology, investigations, management and outcomes. Orbital lymphoma is most often of low-grade histology; thyroid eye disease may predispose and chlamydial infection has been suggested as a trigger. Commonly, stage IE, in most cases, can be managed with radiotherapy alone using either a kilovoltage portal for conjunctival disease or a wedged pair of megavoltage beams for more infiltrative disease to a dose of 30 Gy in 15 fractions over 3 weeks. However, medical therapy is being investigated, including a rituximab-only approach for conjunctival-only presentations. The cure rate for stage IE disease is very high. In contrast, primary ocular lymphoma is often of high-grade histology, in particular diffuse large B-cell lymphoma, and can be regarded as one end of primary central nervous system lymphoma - both eyes and brain being at risk. Immunosuppression predisposes to the disease. Management consists of an initial high-dose chemotherapy regimen with methotrexate. In most cases, this should be followed by radiotherapy to the whole brain and globes to a dose of 30-36 Gy with a boost to bulk/presenting disease. Cure rates are rarely above 50%.

• Authors: D K Woolf, M Ahmed, P N Plowman
• Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) (Clin Oncol (R Coll Radiol)) Vol. 24 Issue 5 Pg. 339-44 (Jun 2012) ISSN: 1433-2981 [Electronic] England
• PMID: 22521959 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012. Published by Elsevier Ltd.

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemoradiotherapy
• Eye Neoplasms (drug therapy, pathology, radiotherapy)
• Humans
• Lymphoma (drug therapy, pathology, radiotherapy)
• Orbital Neoplasms (drug therapy, pathology, radiotherapy)